UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Journal of clinical oncology, 2018-02, Vol.36 (6), p.536-542

2018

Volltextzugriff (PDF)

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

The lancet oncology, 2019-04, Vol.20 (4), p.518-530

2019

Volltextzugriff (PDF)

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

The lancet oncology, 2021-09, Vol.22 (9), p.1290-1300

2021

Volltextzugriff (PDF)

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

Nature genetics, 2017-02, Vol.49 (2), p.170-174

2017

Volltextzugriff (PDF)

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

Cell, 2012-09, Vol.150 (6), p.1121-1134

2012

Volltextzugriff (PDF)

HER2 activating mutations are targets for colorectal cancer treatment

Cancer discovery, 2015-08, Vol.5 (8), p.832-841

2015

Volltextzugriff (PDF)

Genomic Characterization of Primary Invasive Lobular Breast Cancer

Journal of clinical oncology, 2016-06, Vol.34 (16), p.1872-1881

2016

Volltextzugriff (PDF)

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Cancer discovery, 2013-02, Vol.3 (2), p.224-237

2013

Volltextzugriff (PDF)

Whole―genome analysis informs breast cancer response to aromatase inhibition

Nature (London), 2012-06, Vol.486 (7403), p.353-360

2012

Volltextzugriff (PDF)

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Clinical cancer research, 2017-10, Vol.23 (19), p.5687-5695

2017

Volltextzugriff (PDF)

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Cell reports (Cambridge), 2013-09, Vol.4 (6), p.1116-1130

2013

Volltextzugriff (PDF)

The prognostic effects of somatic mutations in ER-positive breast cancer

Nature communications, 2018-09, Vol.9 (1), p.3476-16, Article 3476

2018

Volltextzugriff (PDF)

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

Nature, 2007-11, Vol.450 (7170), p.741-744

2007

Volltextzugriff (PDF)

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Journal of the National Comprehensive Cancer Network, 2019-02, Vol.17 (2), p.141-147

2019

Volltextzugriff (PDF)

Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types

Scientific reports, 2017-07, Vol.7 (1), p.6418-12, Article 6418

2017

Volltextzugriff (PDF)

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

Cancer, 2016-09, Vol.122 (17), p.2654-2662

2016

Volltextzugriff (PDF)

Environmental impact improvements due to introducing automation into underground copper mines

International journal of mining science and technology, 2021-11, Vol.31 (6), p.1159-1167

2021

Volltextzugriff (PDF)

Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System

The Journal of biological chemistry, 2010-03, Vol.285 (10), p.7035-7044

2010

Volltextzugriff (PDF)

Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases

The Journal of biological chemistry, 2017-01, Vol.292 (2), p.597-610

2017

Volltextzugriff (PDF)

Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data

PloS one, 2013-06, Vol.8 (6), p.e67980-e67980

2013

Volltextzugriff (PDF)

Exome Sequencing and cis-Regulatory Mapping Identify Mutations in MAK, a Gene Encoding a Regulator of Ciliary Length, as a Cause of Retinitis Pigmentosa

American journal of human genetics, 2011-08, Vol.89 (2), p.253-264

2011

Volltextzugriff (PDF)

Identification of Targets of c-Src Tyrosine Kinase by Chemical Complementation and Phosphoproteomics

Molecular & cellular proteomics, 2012-08, Vol.11 (8), p.355-369

2012

Volltextzugriff (PDF)

A Neu View of Invasive Lobular Breast Cancer

Clinical cancer research, 2013-07, Vol.19 (13), p.3331-3333

BOSE, Ron

2013

Volltextzugriff (PDF)

1 – 25 von 169

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieProceedings Of The National Academy Of Sciences - Pnas

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(169)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

HER2 activating mutations are targets for colorectal cancer treatment

Genomic Characterization of Primary Invasive Lobular Breast Cancer

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Whole―genome analysis informs breast cancer response to aromatase inhibition

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

The prognostic effects of somatic mutations in ER-positive breast cancer

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

Environmental impact improvements due to introducing automation into underground copper mines

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System

Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data

Exome Sequencing and cis-Regulatory Mapping Identify Mutations in MAK, a Gene Encoding a Regulator of Ciliary Length, as a Cause of Retinitis Pigmentosa

Identification of Targets of c-Src Tyrosine Kinase by Chemical Complementation and Phosphoproteomics

A Neu View of Invasive Lobular Breast Cancer

Aktive Filter

Suchergebnisse filtern